COVID Quick Takes: subcutaneous Regeneron mAbs prevent symptomatic COVID; plus Pfizer-BionTech, J&J, Akili and Kiniksa

Regeneron reported Phase III data Monday showing subcutaneous REGEN-COV met the primary endpoint of preventing symptomatic COVID-19 in the study’s two populations, and the company plans to request an EUA expansion in the preventive setting. 

The current emergency use authorization is for 2,400 mg IV REGEN-COV (casirivimab/imdevimab) to treat outpatients with mild to moderate COVID-19 who are at high risk of progression to more severe disease. ...